BBOT
BridgeBio·NASDAQ
--
--(--)
--
--(--)
BBOT Profile
Bridgebio Oncology Therapeutics, Inc.
A clinical-stage biopharmaceutical company headquartered in South San Francisco,California,USA
256 E. Grand Avenue, Suite 104, South San Francisco, CA 94080
--
BridgeBio Oncology Therapeutics, Inc., was incorporated as a Cayman Islands exempted company on June 15, 2021. Effective August 12, 2025, the Company completed the previously announced Business Combination, with the combined company's place of incorporation in Delaware. BBOT is a clinical-stage biotechnology company whose mission is to transform the lives of cancer patients driven by the two most commonly mutated oncogenes, RAS and PI3Kα.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
